Latest Regulatory Clearance News

Dropsuite secures Foreign Investment Review Board approval for its acquisition by NinjaOne, clearing a major regulatory hurdle ahead of the upcoming shareholder vote. Meanwhile, ASIC grants an extension for Dropsuite’s 2025 AGM, reflecting the pending transaction timeline.

James Hardie Industries plc has entered a definitive merger agreement to acquire The AZEK Company Inc. in a $7.8 billion deal, creating a combined leader in outdoor living and home exteriors. The transaction, expected to close in the second half of 2025, will see AZEK stockholders owning approximately 26% of the combined company.

OD6 Metals has secured regulatory approval to resume exploration at its historic Gulf Creek Copper Project in NSW, with assay results from six completed drill holes expected soon to shape future programs.

Southern Cross Gold Consolidated Ltd has successfully arranged a C$143 million private placement, positioning the company to accelerate development of its Sunday Creek Gold-Antimony Project in Victoria, Australia.

Imricor Medical Systems has initiated its first MRI-guided atrial flutter ablation procedures at Semmelweis University in Budapest, marking a significant expansion of its real-time MRI technology in Europe.

RBR Group Limited has signed a conditional MOU with Field Ready Group to establish a joint venture focused on employability training in Mozambique, supporting major LNG projects including ExxonMobil’s Rovuma LNG. The venture, through RBR’s subsidiary Futuro Skills, aims to enhance local workforce readiness and economic growth.

Genesis Resources has completed its acquisition of full ownership of the Plavica JV in North Macedonia and is progressing environmental studies and exploration planning for multiple Australian tenements ahead of 2025 drilling campaigns.

CZR Resources has terminated its prior deal with Miracle Iron and endorsed a superior A$75 million cash offer from the Rio Tinto-led Robe River Iron Associates JV for its Robe Mesa Project. The company retains promising gold and titanium-vanadium assets while preparing for shareholder approval.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.